Enyglid | European Medicines Agency (EMA)

[ad_1]

Overview

This is a summary of the European public assessment report (EPAR) for Enyglid. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Enyglid.

Enyglid is a diabetes medicine that contains the active substance repaglinide. It is available as tablets (0.5, 1 and 2 mg).

Enyglid is a ‘generic medicine’. This means that Enyglid is similar to a ‘reference medicine’ already authorised in the European Union (EU) called NovoNorm.

Enyglid is used in adults who have type 2 diabetes. It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) is not adequately controlled by diet, weight reduction and exercise. Enyglid may also be used with metformin (another diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.

The medicine can only be obtained with a prescription.

Enyglid is taken before meals, normally up to 15 minutes before each main meal. The dose is adjusted to give the best control. A doctor should regularly test the patient’s blood glucose to find the lowest effective dose. Enyglid can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.

The recommended starting dose is 0.5 mg. This dose may need to be increased after one or two weeks.

If patients are transferred from another diabetes medicine, the recommended starting dose is 1 mg.

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. Enyglid helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.

Because Enyglid is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, NovoNorm. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Enyglid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine’s.

The CHMP concluded that, in accordance with EU requirements, Enyglid has been shown to have comparable quality and to be bioequivalent to NovoNorm. Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk. The Committee recommended that Enyglid be given marketing authorisation.

The European Commission granted a marketing authorisation valid throughout the European Union for Enyglid on 14 October 2009.

For more information about treatment with Enyglid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

English (EN)
(91.57 KB – PDF)

First published: 19/10/2009Last updated: 15/10/2014

View

Product information

English (EN)
(195.49 KB – PDF)

First published: 19/10/2009Last updated: 05/02/2025

View

Latest procedure affecting product information:
N/0000242537

27/01/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(49.36 KB – PDF)

First published: 10/10/2009Last updated: 04/05/2010

View

Product details

Name of medicine: Enyglid
Active substance: repaglinide
International non-proprietary name (INN) or common name: repaglinide
Therapeutic area (MeSH): Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code: A10BX02

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2 diabetes patients who are not satisfactorily controlled on metformin alone.

Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

More information on Enyglid

English (EN)
(66.45 KB – PDF)

First published: 09/07/2007Last updated: 07/12/2012

View

[ad_2]

Source link

Subscribe now

To access premium content

OG NFT Collection Revived, LooksRare NFT Marketplace

Thetan 3M Players, $1M Vulcan Investment, Blankos on MacOS

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

Genesis Worlds Metaverse Review – A 100 Years Project

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead

Alien Worlds Interview With Co-Founder Saro Mckenna